anti-CD7 CAR-T (Lu Daopei Hospital)

Anti-CD7 CAR-T is a chimeric antigen receptor (CAR) T-cell therapy designed to target the CD7 antigen, a transmembrane glycoprotein highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The therapy involves the genetic modification of T cells to express a CAR that specifically recognizes CD7, enabling the immune cells to identify and lyse CD7-positive malignant cells. A significant technical hurdle in the development of anti-CD7 CAR-T is fratricide, where the CAR-T cells target each other due to endogenous CD7 expression; this is typically circumvented by using CRISPR/Cas9 or other gene-editing tools to knock out the CD7 gene in the CAR-T cells. The program at Hebei Yanda Lu Daopei Hospital is currently being evaluated in Phase 1/2 clinical trials for patients with relapsed or refractory T-cell malignancies.

Other names

CD7 CAR-TCD-7 CAR-TCD 7 CAR-TCD7-targeted CAR-TCD-7-targeted CAR-TCD 7-targeted CAR-Tanti-CD7 chimeric antigen receptor T-cell therapyanti-CD-7 chimeric antigen receptor T-cell therapyanti-CD 7 chimeric antigen receptor T-cell therapy